Charles River Laboratories Intl. Inc (CRL) Director Sells $37,990.00 in Stock

Charles River Laboratories Intl. Inc (NYSE:CRL) Director Online Communications Bdirect sold 131,000 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00.

Charles River Laboratories Intl. Inc (NYSE:CRL) traded down $0.10 during trading on Friday, hitting $106.67. 243,500 shares of the stock traded hands, compared to its average volume of 368,267. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories Intl. Inc has a fifty-two week low of $77.61 and a fifty-two week high of $119.05. The stock has a market cap of $5,056.79, a PE ratio of 26.02, a P/E/G ratio of 1.56 and a beta of 0.88.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the company posted $1.18 EPS. Charles River Laboratories Intl.’s revenue was up 9.0% on a year-over-year basis. research analysts anticipate that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in CRL. YorkBridge Wealth Partners LLC lifted its stake in shares of Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 548 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Charles River Laboratories Intl. by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares during the last quarter. Riverhead Capital Management LLC lifted its stake in shares of Charles River Laboratories Intl. by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the last quarter. Finally, Zions Bancorporation acquired a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at $212,000. 96.12% of the stock is owned by institutional investors and hedge funds.

Several research firms have weighed in on CRL. Evercore ISI began coverage on shares of Charles River Laboratories Intl. in a research report on Thursday. They set an “in-line” rating and a $117.00 price objective on the stock. Argus started coverage on shares of Charles River Laboratories Intl. in a report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price target on the stock. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Bank of America lowered their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Finally, Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a report on Monday, November 13th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $112.75.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories Intl. Inc (CRL) Director Sells $37,990.00 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/19/charles-river-laboratories-intl-inc-crl-director-sells-37990-00-in-stock.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply